AbbVie Inc. entered into an underwriting agreement on Feb. 24, 2026 to issue and sell multiple series of senior notes, including $750 million of senior floating rate notes due 2028, $1.5 billion of 3.775% senior notes due 2028, $1.25 billion of 4.125% senior notes due 2031, $1.25 billion of 4.400% senior notes due 2033, $1.5 billion of 4.750% senior notes due 2036, $1.25 billion of 5.550% senior notes due 2056, and $500 million of 5.650% senior notes due 2066. The offering is expected to close on March 4, 2026, and AbbVie expects net proceeds of about $7.95 billion to repay amounts outstanding under its $4.0 billion 364-day delayed draw term loan facility and for general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-020643), on February 26, 2026, and is solely responsible for the information contained therein.